Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$60.81 USD
+0.82 (1.37%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $62.20 +1.39 (2.29%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HALO 60.81 +0.82(1.37%)
Will HALO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Other News for HALO
Q2 2025 Halozyme Therapeutics Inc Earnings Call Transcript
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insight
Halozyme Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Halozyme (HALO) Surpasses Q2 Revenue Expectations with Strong Therapy Performance
Earnings Scheduled For August 5, 2025